Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / COM
-
Number of holders
-
15
-
Total 13F shares, excl. options
-
607K
-
Shares change
-
+607K
-
Total reported value, excl. options
-
$15.6M
-
Value change
-
+$15.6M
-
Number of buys
-
14
-
Price
-
$25.69
Significant Holders of GYRE THERAPEUTICS, INC. - COM (GYRE) as of Q4 2023
16 filings reported holding GYRE - GYRE THERAPEUTICS, INC. - COM as of Q4 2023.
GYRE THERAPEUTICS, INC. - COM (GYRE) has 15 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 607K shares
.
Largest 10 shareholders include VANGUARD GROUP INC (198K shares), BlackRock Inc. (182K shares), GEODE CAPITAL MANAGEMENT, LLC (134K shares), NORTHERN TRUST CORP (24.6K shares), Parallax Volatility Advisers, L.P. (19.9K shares), RENAISSANCE TECHNOLOGIES LLC (17.1K shares), STATE STREET CORP (14.3K shares), CITIGROUP INC (7.75K shares), Qube Research & Technologies Ltd (6.75K shares), and Tower Research Capital LLC (TRC) (666 shares).
This table shows the top 15 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.